Global Oncology Monitors

Capturing real-world anti-cancer drug treatment since 1991

oncology ward signposting in a hospital

In a highly dynamic therapy area like oncology, you need access to a real-world evidence source you can trust…

Ipsos’ Global Oncology Monitor, which provides gold-standard data with bespoke analyses and recommendations, is used by today’s leading oncology manufacturers to guide their key business decisions. Why…?

About the Ipsos Global Oncology Monitor

  • 30+ years of real-world anti-cancer prescribing data
  • All solid tumours & haematological malignancies covered
  • Running in 30+ markets, with globally comparable metrics & regional nuances
  • Led & serviced by dedicated oncology specialists in all regions
  • All analyses & deliverables fully customised to individual client need.
  • The cost efficiency, robustness and impartiality of multi-client research

Oncology Molecular Diagnostics (MDx) Monitor & Other Solutions

Ipsos offers multiple additional studies that address specific oncology business needs, many of which leverage the Global Oncology Monitor framework. These include:  

  • Oncology MDx Monitor
    Tracks the ongoing evolution of the MDx market and its impact on cancer therapy  
  • Oncology Rapid Fire
    Fast-turnaround deep-dives into specific patient populations  
  • Oncology Dashboards
    Interactive tools covering key oncology metrics such as drug uptake, patient & physician profiling, market sizing, source of business, patient journey, market maps, and more.

The Global Oncology Monitor is part of Ipsos Global Healthcare Monitors, formerly Ipsos’ Global Syndicated Services
 

Recent thought leadership
Paper & Podcast: Mastering Complexity: The Path to a Cancer-free Reality
PoV: PD-L1 Status from the Perspective of Doctors Treating NSCLC     
Paper: Oncology: The Disease, Dynamics & Challenges of Marketing & MR 
Paper: The Power of Holistic Insights in Oncology  
ASCO 2024 Abstract: Physician Justification for Anti-Cancer Treatment Decisions 
ASCO 2023 Poster: Patient Access to Precision Medicine in NSCLC

Tell us your oncology business question today.